Cargando…

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies

AIMS: The availability of specific antibody-based test systems is essential to testing of HER2 protein expression. Here, we mapped epitopes recognized by three pharmacodiagnostic HER2 antibodies and investigated their specificity towards peptides and fusion proteins homologous to the intracellular d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrohl, Anne-Sofie, Pedersen, Hans Christian, Jensen, Sussie Steen, Nielsen, Signe Lykke, Brünner, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263426/ https://www.ncbi.nlm.nih.gov/pubmed/22092409 http://dx.doi.org/10.1111/j.1365-2559.2011.04034.x

Ejemplares similares

Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody
por: Smith, David Hersi, et al.
Publicado: (2014)

Comparative Analysis of Evolutionarily Conserved Motifs of Epidermal Growth Factor Receptor 2 (HER2) Predicts Novel Potential Therapeutic Epitopes
por: Deng, Xiaohong, et al.
Publicado: (2014)

Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
por: Schrohl, Anne-Sofie, et al.
Publicado: (2009)

Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression
Publicado: (1984)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation
por: Haverland, Nicole, et al.
Publicado: (2010)

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
por: Jandu, Haatisha, et al.
Publicado: (2016)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
por: Gouvea, Maria da Penha Gomes, et al.
Publicado: (2022)

Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study
por: Thorsen, Stine B, et al.
Publicado: (2013)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

A combination of two antibodies recognizing non‐overlapping epitopes of HER2 induces kinase activity‐dependent internalization of HER2
por: Szymanska, Monika, et al.
Publicado: (2016)

Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.
por: Ellis, I. O., et al.
Publicado: (1987)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
por: Xiao, Hongmei, et al.
Publicado: (2019)

Genome Editing Reveals Idiosyncrasy of CNGA2 Ion Channel-Directed Antibody Immunoreactivity Toward Oxytocin
por: Blechman, Janna, et al.
Publicado: (2018)

Immunoreactive peptide maps of SARS-CoV-2
por: Mishra, Nischay, et al.
Publicado: (2021)

Merkel Cell Carcinoma Display PIEZO2 Immunoreactivity
por: García-Mesa, Yolanda, et al.
Publicado: (2022)

Immunoreaction at 43 kDa with Anti‐ubiquitin Antibody in Breast Neoplasms
por: Iwaya, Keiichi, et al.
Publicado: (1997)

Peptidomimetic-based antibody surrogate for HER2
por: Zheng, Mengmeng, et al.
Publicado: (2021)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
por: Steffensen, Karina Dahl, et al.
Publicado: (2010)

Distribution of Alarin Immunoreactivity in the Mouse Brain
por: Eberhard, Nicole, et al.
Publicado: (2011)

Immunoreactive cutaneous sporotrichosis()()
por: Carvalho, Gustavo de Sá Menezes, et al.
Publicado: (2020)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
por: Ram, Sripad, et al.
Publicado: (2014)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
por: Mudgal, Shikha, et al.
Publicado: (2023)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Ewing Sarcoma and Ewing-Like Sarcoma and the Role of NKX2.2 Immunoreactivity
por: Ullah, Asad, et al.
Publicado: (2021)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_opapn64g3uqtfol7c31fqq4bop